• Gabapentin;
  • opioid;
  • opium dependence;
  • opioid withdrawal;
  • withdrawal;
  • withdrawal symptoms


Aims  Evaluation of the efficacy of gabapentin in patients undergoing out-patient treatment for opiate withdrawal.

Design  A 3-week double-blind, randomized, placebo-controlled trial of adjunctive gabapentin in methadone-assisted detoxification (MAD).

Setting  Specialized Addictive Behaviors Unit, an out-patient unit for the treatment of patients with an addictive disorder serving the city of Isfahan (Iran).

Participants  Forty out-patients, 37 males and three females, aged 21–61 years, who met DSM-IV criteria for opiate dependence.

Intervention  Random assignment of subjects to receive adjunctive treatment with either gabapentin (900 mg/day) or placebo under double-blind conditions.

Measurements  Severity of subjective withdrawal symptoms using the Subjective Opiate Withdrawal Scale at six stages.

Findings  Despite the superiority of gabapentin on controlling some of withdrawal symptoms, no significant differences were reported between two groups.

Conclusions  Dosage of 900 mg/day of gabapentin is not significantly superior to placebo in controlling opiate withdrawal symptoms.